FDA 483 - New York Blood Center Enterprises - February 11, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
New York Blood Center, Inc. in Long Island City, NY, was inspected for human cord blood processing and received a Form 483 with four observations. The inspection revealed significant issues with laboratory controls, including a lack of sound specifications and failure to follow established procedures, leading to miscalculated results for cord blood units. Additionally, the firm failed to thoroughly investigate discrepancies and had inadequate donor screening for communicable disease risk factors like Zika virus.
ID · 3e5035ef-b0ef-43ea-b48b-39547a2005ad